Patents by Inventor Peter Gergely
Peter Gergely has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240126373Abstract: A hand-tracking platform generates gesture components for use as user inputs into an application of an Augmented Reality (AR) system. In some examples, the hand-tracking platform generates real-world scene environment frame data based on gestures being made by a user of the AR system using a camera component of the AR system. The hand-tracking platform recognizes a gesture component based on the real-world scene environment frame data and generates gesture component data based on the gesture component. The application utilizes the gesture component data as user input in a user interface of the application.Type: ApplicationFiled: October 12, 2022Publication date: April 18, 2024Inventors: Attila Alvarez, Márton Gergely Kajtár, Peter Pocsi, Jennica Pounds, David Retek, Zsolt Robotka
-
Patent number: 11224604Abstract: The present invention relates to a method of treating patients who undergo hematopoietic stem cell transplantation (HSCT) with peripheral blood mobilized stem cells for hematological malignancies and for whom the risk for severe acute graft versus host disease (GVHD) is considerable.Type: GrantFiled: January 29, 2018Date of Patent: January 18, 2022Assignee: PRIOTHERA LIMITEDInventors: Peter Gergely, Kazuhiko Kuriyama
-
Publication number: 20210346317Abstract: The present invention relates to a method of accelerating stem cell engraftment in a patient in need of hematopoietic stem cell transplantation.Type: ApplicationFiled: May 25, 2021Publication date: November 11, 2021Applicant: PRIOTHERA LIMITEDInventors: Christoph BUCHER, Peter GERGELY, Andreas KATOPODIS, Philip SMITH
-
Publication number: 20210283073Abstract: A pharmaceutical preparation that inhibits recurrence of hematological malignancies and/or improves survival rates, in patients who have undergone hematopoietic stem cell transplantation for the treatment of hematological malignancies, which contains 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl] ethyl-propane-1,3-diol or a pharmaceutically acceptable salt thereof as an active ingredient.Type: ApplicationFiled: July 26, 2019Publication date: September 16, 2021Applicant: Priothera LimitedInventors: Claudia CORRADO, Christoph BUCHER, Julie JONES, Peter GERGELY
-
Publication number: 20200306244Abstract: The present disclosure relates to a Wingless-type (wnt) inhibitor of formula (I) for use in the treatment of fibrosis and some fibrosis mediated disorders such as stiff skin syndrome and systemic sclerosis. The present disclosure also provides a method for the treatment of fibrosis, a pharmaceutical combination comprising a wnt inhibitor of formula (I) and a second active ingredient for use in the treatment of fibrosis and also the use of a wnt inhibitor of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of fibrosis and fibrosis mediated disorders.Type: ApplicationFiled: June 20, 2017Publication date: October 1, 2020Applicant: Novartis AGInventors: Jennifer Leslie HARRIS, Peter GERGELY, Jun LIU, Eric SVENSSON
-
Publication number: 20190153111Abstract: The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating Sjögren's syndrome, by employing anti-CD40 antibodies.Type: ApplicationFiled: November 1, 2018Publication date: May 23, 2019Inventors: Pascal Espie, Peter Gergely, James Rush
-
Publication number: 20190022033Abstract: The present invention relates to a method of accelerating stem cell engraftement in a patient in need of hematopoietic stem cell transplantation.Type: ApplicationFiled: March 6, 2017Publication date: January 24, 2019Inventors: Christoph BUCHER, Peter GERGELY, Andreas KATOPODIS, Philip SMITH
-
Publication number: 20180161290Abstract: A compound of formula I: wherein X is O, S, SO or SO2; R1 is halogen, trihalomethyl, —OH, C1-7alkyl, C1-4alkoxy, trifluoromethoxy, phenoxy, cyclohexylmethyloxy, pyridylmethoxy, cinnamyloxy, naphthylmethoxy, phenoxymethyl, —CH2—OH, —CH2CH2—OH, C1-4alkylthio, C1-4alkylsulfonyl, benzylthio, acetyl, nitro or cyano, or phenyl, phenylC1-4alkyl or phenyl-C1-4alkoxy each phenyl group thereof being optionally substituted by halogen, CF3, C1-4alkyl or C1-4alkoxy; R2 is H, halogen, trihalomethyl, C1-4alkoxy, C1-7alkyl, phenethyl or benzyloxy; R3 H, halogen, CF3, OH, C1-7alkyl, C1-4alkoxy, benzyloxy, phenyl or C1-4alkoxymethyl; each of R4 and R5, independently is H or a residue of formula (a) wherein each of R8 and R9, independently, is H or C1-4alkyl optionally substituted by halogen; and n is an integer from 1 to 4; or a pharmaceutically acceptable salt, hydrate, solvate, isomer or prodrug thereof; or a compound of formula II wherein R1a is halogen, trihalomethyl, C1-4alkyl, C1-4alkoxy, C1-4alkylthio, C1Type: ApplicationFiled: December 7, 2017Publication date: June 14, 2018Inventors: Peter Gergely, Erik Wallstroem, Eric Legangneux
-
Publication number: 20180153911Abstract: The present invention relates to a method of treating patients who undergo hematopoietic stem cell transplantation (HSCT) with peripheral blood mobilized stem cells for hematological malignancies and for whom the risk for severe acute graft versus host disease (GVHD) is considerable.Type: ApplicationFiled: January 29, 2018Publication date: June 7, 2018Inventors: Peter Gergely, Kazuhiko KURIYAMA
-
Publication number: 20170119702Abstract: A compound of formula I: wherein X is O, S, SO or SO2; R1 is halogen, trihalomethyl, —OH, C1-7alkyl, C1-4alkoxy, trifluoromethoxy, phenoxy, cyclohexylmethyloxy, pyridylmethoxy, cinnamyloxy, naphthylmethoxy, phenoxymethyl, —CH2—OH, —CH2—CH2—OH, C1-4alkylthio, C1-4alkylsulfinyl, C1-4alkylsulfonyl, benzylthio, acetyl, nitro or cyano, or phenyl, phenylC1-4alkyl or phenyl-C1-4alkoxy each phenyl group thereof being optionally substituted by halogen, CF3, C1-4alkyl or C1-4alkoxy; R2 is H, halogen, trihalomethyl, C1-4alkoxy, C1-7alkyl, phenethyl or benzyloxy; R3 H, halogen, CF3, OH, C1-7alkyl, C1-4alkoxy, benzyloxy, phenyl or C1-4alkoxymethyl; each of R4 and R5, independently is H or a residue of formula (a) wherein each of R8 and R9, independently, is H or C1-4alkyl optionally substituted by halogen; and n is an integer from 1 to 4; or a pharmaceutically acceptable salt, hydrate, solvate, isomer or prodrug thereof; or a compound of formula II wherein R1a is halogen, trihalomethyl, C1-4alkyl, C1-4alkoType: ApplicationFiled: October 19, 2016Publication date: May 4, 2017Applicant: Novartis AGInventors: Peter Gergely, Erik Wallstroem, Eric Legangneux
-
Publication number: 20160175282Abstract: SIP receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.Type: ApplicationFiled: February 26, 2016Publication date: June 23, 2016Inventors: Marco LONDEL, Timothy WRIGHT, Peter GERGELY
-
Publication number: 20160000811Abstract: The present invention relates to a method of treating patients who undergo hematopoietic stem cell transplantation (HSCT) with peripheral blood mobilized stem cells for hematological malignancies and for whom the risk for severe acute graft versus host disease (GVHD) is considerable.Type: ApplicationFiled: February 18, 2014Publication date: January 7, 2016Inventors: Peter GERGELY, Kazuhiko KURIYAMA
-
Patent number: 9149459Abstract: The use of an S1P receptor modulator of the formula (Ia) or (Ib) wherein the meaning of the different residues is that indicated in claim 14, in the preparation of a medicament for preventing, inhibiting or treating an inflammatory condition selected from polymyositis, dermatomyositis and nerve-muscle diseases e.g. muscular dystrophies and inclusion body myositis.Type: GrantFiled: July 22, 2009Date of Patent: October 6, 2015Assignee: Novartis AGInventors: Syed Sohail Ahmed, Marco Londei, Timothy Wright, Peter Gergely
-
Publication number: 20140336265Abstract: A compound of formula I: wherein X is O, S, SO or SO2; R1 is halogen, trihalomethyl, —OH, C1-7alkyl, C1-4alkoxy, trifluoromethoxy, phenoxy, cyclohexylmethyloxy, pyridylmethoxy, cinnamyloxy, naphthylmethoxy, phenoxymethyl, —CH2—OH, —CH2—CH2—OH, C1-4alkylthio, C1-4alkylsulfinyl, C1-4alkylsulfonyl, benzylthio, acetyl, nitro or cyano, or phenyl, phenylC1-4alkyl or phenyl-C1-4alkoxy each phenyl group thereof being optionally substituted by halogen, CF3, C1-4alkyl or C1-4alkoxy; R2 is H, halogen, trihalomethyl, C1-4alkoxy, phenethyl or benzyloxy; R3 H, halogen, CF3, OH, C1-7alkyl, C1-4alkoxy, benzyloxy, phenyl or C1-4alkoxymethyl; each of R4 and R5, independently is H or a residue of formula (a) wherein each of R8 and R9, independently, is H or C1-4alkyl optionally substituted by halogen; and n is an integer from 1 to 4; or a pharmaceutically acceptable salt, hydrate, solvate, isomer or prodrug thereof; or a compound of formula II wherein R1a is halogen, trihalomethyl, C1-4alkyl, C1-4alkoxType: ApplicationFiled: July 28, 2014Publication date: November 13, 2014Applicant: NOVARTIS AGInventors: Peter Gergely, Erik Wallstroem, Eric Legangneux
-
Publication number: 20130210924Abstract: A compound of formula (I) wherein X is O, S, SO or SO2; R1 is halogen, trihalomethyl, —OH, C1-7alkyl, C1-4alkoxy, trifluoromethoxy, phenoxy, cyclohexylmethyloxy, pyridylmethoxy, cinnamyloxy, naphthylmethoxy, phenoxymethyl, —CH2—OH, —CH2—CH2—OH, C1-4alkylthio, C1-4alkylsulfinyl, C1-4alkylsulfonyl, benzylthio, acetyl, nitro or cyano, or phenyl, phenylC1-4alkyl or phenyl-C1-4alkoxy each phenyl group thereof being optionally substituted by halogen, CF3, C1-4alkyl or C1-4alkoxy; R2 is H, halogen, trihalomethyl, C1-4alkoxy, C1-7alkyl, phenethyl or benzyloxy; R3H, halogen, CF3, OH, C1-7alkyl, C1-4alkoxy, benzyloxy, phenyl or C1-44alkoxymethyl; each of R4 and R5, independently is H or a residue of formula (a) wherein each of R8 and R9, independently, is H or C1-4alkyl optionally substituted by halogen; and n is an integer from 1 to 4; or a pharmaceutically acceptable salt, hydrate, solvate, isomer or prodrug thereof; or a compound of formula (II) wherein R1a is halogen, trihalomethyl, C1-4alkyl, C1-4alkoxy, C1-4alkylType: ApplicationFiled: May 5, 2011Publication date: August 15, 2013Applicant: NOVARTIS AGInventors: Peter Gergely, Erik Wallstroem, Eric Legangneux
-
Publication number: 20130172297Abstract: Disclosed is the use of a compound of formula I wherein X is O, S, SO or SO2; R1 is halogen, trihalomethyl, —OH, C1-7alkyl, C1-4alkoxy, trifluoromethoxy, phenoxy, cyclohexylmethyloxy, pyridylmethoxy, cinnamyloxy, naphthylmethoxy, phenoxymethyl, —CH2—OH, —CH2—CH2—OH, C1-4alkylthio, C1-4alkyl-sulfinyl, C1-4alkylsulfonyl, benzylthio, acetyl, nitro or cyano, or phenyl, phenylC1-4alkyl or phenyl-C1-4alkoxy each phenyl group thereof being optionally substituted by halogen, CF3, C1-4alkyl or C1-4alkoxy; R2 is H, halogen, trihalomethyl, C1-4alkoxy, C1-7alkyl, phenethyl or benzyloxy; R3H, halogen, CF3, OH, C1-7alkyl, C1-4alkoxy, benzyloxy, phenyl or C1-4alkoxymethyl; each of R4 and R5, independently is H or a residue of formula (a) wherein each of R8 and R9, independently, is H or C1-4alkyl optionally substituted by halogen; and n is an integer from 1 to 4; or a pharmaceutically acceptable salt, hydrate, solvate, isomer or prodrug thereof; or a compound of formula II wherein R1a is halogen, trihalomethyl, C1-4alkyl, CType: ApplicationFiled: May 5, 2011Publication date: July 4, 2013Applicant: NOVARTIS AGInventors: Peter Gergely, Erik Wallstroem
-
Publication number: 20110124620Abstract: The use of an S1P receptor modulator of the formula (Ia) or (Ib) wherein the meaning of the different residues is that indicated in claim 14, in the preparation of a medicament for preventing, inhibiting or treating an inflammatory condition selected from polymyositis, dermatomyositis and nerve-muscle diseases e.g. muscular dystrophies and inclusion body myositis.Type: ApplicationFiled: July 22, 2009Publication date: May 26, 2011Inventors: Syed Sohail Ahmed, Marco Londel, Timothy Wright, Peter Gergely